Good morning, and welcome to the Arcus Biosciences, Inc. virtual stockholder meeting. I would now like to introduce the first presenter, Terry Rosen. Morning. I'm Terry Rosen, Chairman of the Board and Chief Executive Officer of Arcus Biosciences. I'm very happy to welcome you to the Arcus Biosciences 2026 Annual Meeting of Stockholders. The meeting will now officially come to order. The time is now 8:30 A.M. on Thursday, June 11, 2026. The polls are now open for voting on all matters to be presented. Before I proceed with the formal business of the meeting, I'd like to note that in addition to myself, we have the following members of the board in attendance today: Linda Higgins, Yasunori Kaneko, David Lacey, Nicole Lambert, Patrick Machado, Johanna Mercier, Andy Perlman, and Antoni Ribas. Also joining us today are Juan Jaen, our President and Head of Research, Bob Goeltz, our Chief Financial Officer, Richard Markus, our Chief Medical Officer, Carolyn Tang, our General Counsel, Alexander Azoy, our Chief Accounting Officer, and representatives of Ernst & Young, the company's auditors. Carolyn Tang will be serving as the secretary of this meeting, and Kathy Blackwell will be serving as inspector of elections. Guests to the meeting will not be able to ask questions. For stockholders who have joined the meeting using their 16-digit control number, to ask a question, click on the Ask a Question prompt on your screen to submit your question or comment online. We will answer questions submitted that are germane to the proposals and/or this meeting as and if we have time. Please submit your questions now to make sure they're received in a timely fashion for our review and response. We will now proceed with the formal business of the meeting as set forth in your Notice of Annual Meeting and Proxy Statement. Will the secretary please report at this time with respect to the mailing of the notice of the meeting and the stockholders list? I have at this meeting a complete list of the stockholders of record of the company's common stock on April 16th, 2026. You may disconnect the record date for this meeting. I also have an affidavit certifying that a notice of annual meeting of stockholders of the company was deposited in the U.S. mail to all stockholders of record at the close of business on April 21st, 2026. Kathy Blackwell is hereby appointed inspector of election for this meeting. She has taken and subscribed the customary oath of office to execute her duties with strict impartiality. We will file this oath with the records of the meeting. Her function is to decide upon the qualifications of voters, accept their votes, and when balloting on all matters is completed, to tally the final votes. Ms. Tang, would you please confirm the existence of a quorum? The inspector of election has confirmed that proxies have been received for 117,860,757 of the 125,628,682 shares of common stock outstanding on the record date, which represents approximately 94% of the total number of outstanding shares. This constitutes a quorum for the meeting today. We may now carry out the official business of the meeting. If you have already submitted your vote by proxy and do not wish to change your vote, you do not need to vote now and your shares will be voted as previously instructed. If you intend to vote and have not already done so, you must submit your vote online now for it to be counted. If you have not voted, I encourage you to vote now online. There are three proposals to be considered by the stockholders at this meeting. The first item of business is the election of directors to serve until the 2029 annual meeting and until their respective successor is elected. The nominees are Dr. Dietmar Berger, Dr. David Lacey, Nicole Lambert, and Johanna Mercier. The second item of business today is the ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young as the independent auditors of the company for the fiscal year ending December 31, 2026. The third item of business today is the approval on an advisory basis of the compensation of Arcus's named executive officers. That was the final proposal for today's meeting. We will now review if there are any questions submitted about the proposals before we close the polls. As a reminder, we will only review and answer questions at this time that pertain to the proposals. There are no questions related to the proposals. The time is now 8:34 A.M. The polls are now closed for voting. Based on the preliminary voting results, the proposal to elect Dr. Berger, Dr. Lacey, Ms. Lambert, and Ms. Mercier is carried. The appointment of Ernst & Young as the independent auditors for the fiscal year ending December 31, 2026 is ratified. The approval on an advisory basis of the compensation of the company's named executive officers is carried. A full tally of the final votes will be published in a current report on Form 8-K, which will be filed with the Securities and Exchange Commission on or before June 17th, 2026. This concludes the Arcus Biosciences 2026 virtual stockholder meeting. This meeting is now concluded. Thank you all for joining. You may now disconnect.